B. Hargadon

发表

Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography

I. Gut, Dave Singh, D. Subramanian, 2016, European Respiratory Journal.

Cohort Profile: Extended Cohort for E-health, Environment and DNA (EXCEED)

Emma L Adams, Catherine E Bee, L. Wain, 2018, bioRxiv.

Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma.

I. Pavord, C. Newby, B. Hargadon, 2014, The Journal of allergy and clinical immunology.

Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study

I. Pavord, D. Shaw, B. Hargadon, 2014, European Respiratory Journal.

Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis

B. Hargadon, C. Brightling, J. Eastham‐Anderson, 2018, The Journal of allergy and clinical immunology.

A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma.

I. Pavord, D. Shaw, B. Hargadon, 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

Volatile organic compounds in a headspace sampling system and asthmatics sputum samples

B. Hargadon, C. Brightling, P. Monks, 2020, Journal of breath research.

Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma.

B. Hargadon, Alexander R. Abbas, Lawren C. Wu, 2012, The Journal of allergy and clinical immunology.

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

I. Pavord, S. Birring, B. Hargadon, 2005, Thorax.

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial

I. Pavord, B. Hargadon, C. Brightling, 2007, European Respiratory Journal.

Sputum eosinophilia in idiopathic pulmonary fibrosis

I. Pavord, S. Birring, B. Hargadon, 2005, Inflammation Research.

Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis.

B. Hargadon, P. Bradding, P. Mallinder, 2005, Mutation research.

Profiling of Sputum Inflammatory Mediators in Asthma and Chronic Obstructive Pulmonary Disease

B. Hargadon, C. Brightling, M. Bafadhel, 2011, Respiration.

Lung Computational Models and the Role of the Small Airways in Asthma.

B. Hargadon, C. Brightling, D. Kay, 2019, American journal of respiratory and critical care medicine.

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma

B. Hargadon, P. Bradding, A. Wardlaw, 2017, Chronic respiratory disease.

Airway dysfunction and inflammation in pool- and non-pool-based elite athletes.

I. Pavord, B. Hargadon, M. Lindley, 2012, Medicine and science in sports and exercise.

Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma

I. Pavord, D. Shaw, B. Hargadon, 2005, European Respiratory Journal.

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

I. Pavord, A. Woodcock, P. Howarth, 2020, The Lancet. Respiratory medicine.

Evidence of a role of tumor necrosis factor alpha in refractory asthma.

I. Pavord, D. Shaw, B. Hargadon, 2006, The New England journal of medicine.

Observational study of the natural history of eosinophilic bronchitis

I. Pavord, D. Shaw, B. Hargadon, 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Exacerbations of severe asthma in patients treated with mepolizumab

I. Pavord, S. Yancey, B. Hargadon, 2018, European Respiratory Journal.

Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation

A. Sousa, B. Hargadon, Richard Graham Knowles, 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Association between neutrophilic airway inflammation and airflow limitation in adults with asthma.

I. Pavord, D. Shaw, B. Hargadon, 2007, Chest.

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

I. Pavord, H. Ortega, S. Gupta, 2014, The Journal of allergy and clinical immunology.

COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils

B. Hargadon, C. Brightling, M. Bafadhel, 2014, BMC Pulmonary Medicine.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, Steve B Jones, K. Y. Wong, 2021, The Lancet.

A placebo controlled comparison of formoterol, montelukast or higher dose of inhaled corticosteroids in subjects with symptomatic asthma despite treatment with low dose inhaled corticosteroids

I. Pavord, B. Hargadon, C. Brightling, 2002 .

Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1.

I. Pavord, B. Hargadon, C. Brightling, 2012 .

Vascular remodelling is a feature of asthma and non-asthmatic eosinophilic bronchitis

I. Pavord, B. Hargadon, C. Brightling, 2006 .

Airway function and markers of airway inflammation in patients with treated hypothyroidism

S. Birring, B. Hargadon, I. Pavord, 2005, Thorax.

Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker‐high and ‐low severe asthma

I. Pavord, P. Howarth, F. Symon, 2022, Allergy.

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial

Robert J. Mackenzie, Patrick M Liu, M. Haynes, 2022, The Lancet Respiratory Medicine.

Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study).

I. Pavord, B. Hargadon, C. Brightling, 2014, The Journal of allergy and clinical immunology.

Severe exacerbations in moderate-to-severe asthmatics are associated with increased pro-inflammatory and type 1 mediators in sputum and serum

C. Newby, B. Hargadon, C. Brightling, 2019, BMC Pulmonary Medicine.

Podium # 6 Exhaled Nitric Oxide is a Good , Non-Invasive Test for Steroid Responsive Airways Disease in Elite Swimmers

B. Hargadon, J. Vilas-Boas, M. Lindley, 2012 .

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial

I. Pavord, B. Hargadon, C. Brightling, 2002, The Lancet.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma

J. Egen, B. Hargadon, Alexander R. Abbas, 2015, Science Translational Medicine.

Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1

I. Pavord, B. Hargadon, C. Brightling, 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma.

I. Pavord, B. Hargadon, C. Brightling, 2010, American journal of respiratory and critical care medicine.

Visualisation of exhaled breath metabolites reveals distinct diagnostic signatures for acute cardiorespiratory breathlessness

N. Samani, B. Hargadon, C. Brightling, 2022, Science Translational Medicine.

Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study

Salman Siddiqui, Leong L Ng, Christopher E Brightling, 2019, BMJ Open.

OP-IJEJ190076_cohort 678..689

L. Wain, N. Shrine, I. Ntalla, 2019 .

Cohort Profile Cohort Profile : Extended Cohort for E-health , Environment and DNA ( EXCEED )

Christopher E Brightling, Susan E Wallace, Edward J Hollox, 2019 .

Mepolizumab and exacerbations of refractory eosinophilic asthma.

Ana Sousa, Christopher E Brightling, Peter Bradding, 2009, The New England journal of medicine.

Diagnosis of COVID-19 by exhaled breath analysis using gas chromatography–mass spectrometry

B. Hargadon, C. Brightling, P. Monks, 2021, ERJ Open Research.

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study.

A. L. Tan, Sally J. Singh, C. Sudlow, 2021, The Lancet. Respiratory medicine.

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness

I. Pavord, I. Hall, B. Hargadon, 2006, European Respiratory Journal.

A feasibility study of a randomised controlled trial of asthma-tailored pulmonary rehabilitation compared with usual care in adults with severe asthma.

Sally J. Singh, B. Hargadon, P. Bradding, 2020, The journal of allergy and clinical immunology. In practice.

Body Mass and Fat Mass in Refractory Asthma: An Observational 1 Year Follow-Up Study

I. Pavord, B. Hargadon, C. Brightling, 2010, Journal of allergy.

A CEACAM6-High Airway Neutrophil Phenotype and CEACAM6-High Epithelial Cells Are Features of Severe Asthma

B. Hargadon, Alexander R. Abbas, Lawren C. Wu, 2017, The Journal of Immunology.

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

Paul J. Harrison, Gary F. Simons, A. L. Tan, 2023, The Lancet Regional Health - Europe.

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

Gary F. Simons, A. L. Tan, L. Wain, 2023, eClinicalMedicine.

P20 The eligibility of patients with difficult asthma for omalizumab since the change to the treatment criteria

B. Hargadon, I. Pavord, R. Green, 2010, Thorax.

Corrigendum to: Cohort profile: Extended Cohort for E-health, Environment and DNA (EXCEED)

L. Wain, N. Shrine, I. Ntalla, 2019, International journal of epidemiology.

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

Paul J. Harrison, Gary F. Simons, A. L. Tan, 2023, The Lancet Respiratory Medicine.

Isolation of Aspergillus fumigatus from sputum is associated with elevated airborne levels in homes of patients with asthma.

B. Hargadon, A. Wardlaw, A. Fairs, 2013, Indoor air.

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

Paul J. Harrison, Jennifer M. Brown, Gary F. Simons, 2022, The Lancet. Respiratory medicine.

Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography

I. Gut, Dave Singh, D. Subramanian, 2016, European Respiratory Journal.

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

K. C. Morris, Michele R. Shaw, Mohammed Salah Ibrahim, 2023, The Lancet.

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

K. Y. Wong, Mohammad A. Qayum, John S. Clouston, 2022, Lancet.

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

K. Y. Wong, Beverley E. Crane, Scott M Elliott, 2021, Lancet.

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Panteleimon G. Takis, Jordan J. Clark, Michael J. Murphy, 2022, eBioMedicine.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

S. Birring, B. Hargadon, D. Parker, 2005 .

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Thomas E. Nichols, Paul J. Harrison, Jennifer M. Brown, 2023, The Lancet. Respiratory medicine.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, K. Y. Wong, Ayesha Binte Ashfaq, 2021, Lancet.